— Specialty pharmaceutical company AcelRx Pharmaceuticals (NASDAQ: ACRX) reported fourth quarter 2019 loss of $0.18 per share vs. expected loss of $0.20 per share.
— Revenue was $0.48 million vs. $1.01 million expected.
— AcelRx also announced today about its acquisition of Tetraphase Pharmaceuticals for $14.4 million. This stock for stock deal is expected to close in the second quarter of 2020.
— AcelRx and Tetraphase have also entered into a co-promotion agreement, which will benefit both the teams in promoting multiple products, leveraging each company’s customer relationships, and creating efficiencies among commercial teams prior to the closing of the merger.
— AcelRx expects to achieve its previously communicated target of 465 REMS-certified facilities and formulary approvals by the end of 2020.
— The company expects quarterly combined R&D and SG&A expense in 2020 to range from $10 million to $13 million, depending on the quarter. This estimate includes approximately $1 million of non-cash stock-based compensation per quarter.
— ACRX stock was down more than 10% in the pre-market trading session.
Most Popular
Infographic: Intuitive Surgical Q4 earnings results
Intuitive Surgical (NASDAQ: ISRG) reported fourth-quarter 2020 financial results after the regular market hours on Thursday. The robotic product's manufacturer reported fourth-quarter revenue of $1.33 billion, up 4% year-over-year. Meanwhile,
Infographic: Seagate Technology (STX) Q2 2021 earnings
Seagate Technology plc (NASDAQ: STX) reported second-quarter 2021 earnings results after the closing bell on Thursday. Revenue increased to $2.62 billion from $2.69 billion last year. Analysts had expected revenue
IBM (IBM) Q4 2020 Earnings: Key financials and quarterly highlights
IBM (NYSE: IBM) reported its fourth quarter 2020 earnings results today. Revenue fell 6% year-over-year to $20.4 billion. GAAP net income fell over 60% to $1.3 billion, or $1.51 per
